- George I. Papakostas, MD
This webinar was part of the Virtual Grand Round Series titled: Addressing Unmet Needs in the Treatment of Psychiatric Disorders.
- Recognize key aspects in the assessment of antidepressant therapeutic failure.
- Review evidenced based best practices and associated research findings for increased dosing, augmentation, combination, and switching strategies.
- Identify neurotherapeutic treatment options for refractory depression.
Psychiatrists, primary care/family physicians, nurses, allied healthcare professionals
Director of Treatment-Resistant Depression Studies, Department of Psychiatry, MGH
Associate Professor of Psychiatry, Harvard Medical School
This program is not accredited.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. CME credit is not being offered for this activity.
Even though this event is not accredited, providing information regarding planning, disclosure, and conflict of interest is important to us. Some providers may be able to claim Category 2 CME credit for participating in this activity.
FACULTY DISCLOSURE STATEMENTS
In accord with the guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.
RESOLUTION OF CONFLICTS OF INTEREST (COI)
The MGH Academy has implemented a process to resolve potential COIs for this CME activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.
The following planners and/or their spouse/partner have no relevant financial relationship with a commercial interest:
Tristan Gorrindo, MD: Planner
The following speaker and/or his spouse/partner has reported a relevant financial relationship with a commercial interest:
Consultant: Abbott Laboratories, AstraZeneca PLC, Brainsway Ltd, Bristol-Myers Squibb Company, Cephalon Inc., Dey Pharma, L.P., Eli Lilly Co., GlaxoSmithKline, Evotec AG, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer Inc., Pierre Fabre Laboratories, Ridge Diagnostics (formerly known as Precision Human Biolaboratories), Shire Pharmaceuticals, Takeda Pharmaceutical Company LTD, Theracos, Inc., and Wyeth, Inc.
Honoraria: Abbott Laboratories, Astra Zeneca PLC, Bristol-Myers Squibb Company, Brainsway Ltd, Cephalon Inc., Dey Pharma, L.P., Eli Lilly Co., Evotec AG, GlaxoSmithKline, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, Lundbeck, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer, Pierre Fabre Laboratories, Ridge Diagnostics, Shire Pharmaceuticals, Takeda Pharmaceutical Company LTD, Theracos, Inc., Titan Pharmaceuticals, and Wyeth Inc.
This program was originally developed as an accredited educational activity using support in the form of educational grants from the following companies:
- Janssen Scientific Affairs, LLC
- Lilly USA, LLC
- Sunovion Pharmaceuticals, Inc.
- Takeda Pharmaceutical International, Inc. and Lundbeck
Optimal System Configuration:
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit